Currently out of the existing stock ratings of James Condulis, 30 are a BUY (93.75%), 2 are a HOLD (6.25%).

James Condulis

Work Performance Price Targets & Ratings Chart

Analyst James Condulis, currently employed at STIFEL, has had 29.44% of price targets met with an average potential upside of 37.47%, reached in 102 days on average.

James Condulis has documented 61 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MIRM, Mirum Pharmaceuticals at 15-Oct-2026.

Wall Street Analyst James Condulis

Analyst best performing recommendations are on MIRM (MIRUM PHARMACEUTICALS).
The best stock recommendation documented was for SLNO (SOLENO THERAPEUTICS) on 3/12/2025. The price target of $74 was fulfilled within 43 days with a profit of $27.3 (58.46%), with a performance score of 13.59.

Average potential price target upside

CYTK Cytokinetics EWTX Edgewise Therapeutics MIRM Mirum Pharmaceuticals NAMS NewAmsterdam Pharma Company N.V. SLNO Soleno Therapeutics XFOR X4 Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 15-Aug-2023

$100

$43.87 (78.16%)

$84

13 days ago
(05-Nov-2026)

3/4 (75%)

$36.4 (57.23%)

123

Buy Since 27-Mar-2014

$140

$83.87 (149.42%)

$140

30 days ago
(19-Oct-2026)

44/75 (58.67%)

$77.35 (123.46%)

818

Buy Since 08-Nov-2024

$113

$56.87 (101.32%)

$112

1 months 10 days ago
(08-Oct-2026)

4/11 (36.36%)

$50.99 (82.23%)

448

Buy Since 09-Dec-2022

$103

$46.87 (83.50%)

$97

3 months 5 days ago
(13-Aug-2026)

10/12 (83.33%)

$29.55 (40.23%)

312

Buy Since 20-Dec-2022

$112

$55.87 (99.54%)

$106

3 months 8 days ago
(10-Aug-2026)

6/9 (66.67%)

$34.51 (44.53%)

366

Show more analysts

Please expand the browser size to see the chart

Which stock is James Condulis most bullish on?

Potential upside of $62.01 has been obtained for MIRM (MIRUM PHARMACEUTICALS)

What Year was the first public recommendation made by James Condulis?

On 2025
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?